Sanchez AM, et al. (2009) Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol 23, 1193-202 19460862

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T558-p - Moesin (rat) ▲

Modsite: LGRDKYKtLRQIRQG SwissProt Entrez-Gene Orthologous residues Moesin (human): T558‑p, Moesin (mouse): T558‑p, Moesin (rat): T558‑p, Moesin (chicken): T561‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'neuron, cortical' Cellular systems studied:  primary cultured cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes estradiol increase

S310-p - WAVE1 (rat) ▲

Modsite: LIENRPQsPAAGRTP SwissProt Orthologous residues WAVE1 (human): S310‑p, WAVE1 (mouse): S310‑p, WAVE1 (rat): S310‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'neuron, cortical' Cellular systems studied:  primary cultured cells Species studied:  rat Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK5 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes estradiol ER-alpha (human) increase PPT estradiol ER-alpha (human) no effect upon treatment-induced increase faslodex estradiol ER-alpha (human) inhibit treatment-induced increase DPN estradiol ER-alpha (human) inhibit treatment-induced increase wortmannin estradiol ER-alpha (human) no effect upon treatment-induced increase PD98059 estradiol ER-alpha (human) no effect upon treatment-induced increase PTX estradiol ER-alpha (human) inhibit treatment-induced increase PP2 estradiol ER-alpha (human) inhibit treatment-induced increase seliciclib estradiol ER-alpha (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  cytoskeletal reorganization

S397-p - WAVE1 (rat) ▲

Modsite: APPLVQPsPPVARAA SwissProt Orthologous residues WAVE1 (human): S397‑p, WAVE1 (mouse): S397‑p, WAVE1 (rat): S397‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'neuron, cortical' Cellular systems studied:  primary cultured cells Species studied:  rat Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK5 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes estradiol ER-alpha (human) increase PPT estradiol ER-alpha (human) no effect upon treatment-induced increase faslodex estradiol ER-alpha (human) inhibit treatment-induced increase DPN estradiol ER-alpha (human) inhibit treatment-induced increase wortmannin estradiol ER-alpha (human) no effect upon treatment-induced increase PD98059 estradiol ER-alpha (human) no effect upon treatment-induced increase PTX estradiol ER-alpha (human) inhibit treatment-induced increase PP2 estradiol ER-alpha (human) inhibit treatment-induced increase seliciclib estradiol ER-alpha (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  cytoskeletal reorganization

S441-p - WAVE1 (rat) ▲

Modsite: PPGIRPSsPVTVAAL SwissProt Orthologous residues WAVE1 (human): S441‑p, WAVE1 (mouse): S441‑p, WAVE1 (rat): S441‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  'neuron, cortical' Cellular systems studied:  primary cultured cells Species studied:  rat Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK5 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes estradiol ER-alpha (human) increase PPT estradiol ER-alpha (human) no effect upon treatment-induced increase faslodex estradiol ER-alpha (human) inhibit treatment-induced increase DPN estradiol ER-alpha (human) inhibit treatment-induced increase wortmannin estradiol ER-alpha (human) no effect upon treatment-induced increase PD98059 estradiol ER-alpha (human) no effect upon treatment-induced increase PTX estradiol ER-alpha (human) inhibit treatment-induced increase PP2 estradiol ER-alpha (human) inhibit treatment-induced increase seliciclib estradiol ER-alpha (human) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  cytoskeletal reorganization